Interim Report 2026
Filed with HKEX · Stock code 2268 · · 117 pages · English
Corporate Information Financial Highlights Corporate Profile Management Discussion and Analysis Other Information Report on Review of Condensed Consolidated Financial Statements 61 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 63 Condensed Consolidated Statement of Financial Position 65 Condensed Consolidated Statement of Changes in Equity 67 Condensed Consolida
Earlier from WuXi XDC Cayman
- WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
- WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
- WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
- Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
- WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
Later from WuXi XDC Cayman
- WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow WuXi XDC Cayman into a list and get an email when it puts out news.
Follow WuXi XDC Cayman